Tags

Type your tag names separated by a space and hit enter

Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma.
Scand J Gastroenterol 2007; 42(8):933-40SJ

Abstract

OBJECTIVE

Helicobacter pylori infection is an established risk factor for non-cardia gastric adenocarcinoma. Infection with H. pylori strains harbouring the cagA pathology island may augment this association. H. pylori infection may at the same time reduce the risk for oesophageal carcinoma. However, prospective data on the association between CagA seropositivity and gastric or oesophageal carcinomas are limited. The purpose of this study was to investigate whether CagA seropositivity among H. pylori seropositive subjects is associated with gastric or oesophageal carcinomas.

MATERIAL AND METHODS

A nested case-control study was performed in the Malmö Preventive Medicine cohort consisting of 32,906 middle-aged subjects. Tumour cases were identified by the Swedish National Cancer Registry. The Western blot method Helicoblot 2.1 was used to detect H. pylori and CagA seropositivity.

RESULTS

Non-cardia gastric adenocarcinoma was associated with H. pylori seropositivity, odds ratio 17.8 (95% CI: 4.2-74.8; 67 cases). The odds ratio for CagA seropositivity among H. pylori seropositive subjects was 9.7 (95% CI: 1.5-infinity). No significant associations were found between cardia gastric adenocarcinoma and H. pylori or CagA seropositivity among H. pylori seropositive subjects; odds ratios were 1.5 (95% CI: 0.51-4.8) and 2.7 (95% CI: 0.38-infinity), respectively (24 cases). Oesophageal adenocarcinoma and oesophageal squamous cell carcinoma were not significantly associated with H. pylori seropositivity or with CagA seropositivity among H. pylori seropositive subjects; the odds ratios associated with oesophageal adenocarcinoma were 0.46 (95% CI: 0.07-2.6) and 0.38 (95% CI: 0.02-24), respectively. Corresponding odds ratios for oesophageal squamous cell carcinoma were 0.44 (95% CI: 0.15-1.2; 37 cases) and 2.0 (95% CI: 0.24-infinity), respectively.

CONCLUSIONS

CagA seropositivity among H. pylori seropositive subjects is a risk factor for non-cardia gastric adenocarcinoma.

Authors+Show Affiliations

Department of Medicine, Malmö University Hospital, Lund University, Malmö, Sweden. Henrik.Siman@med.lu.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17613922

Citation

Simán, J Henrik, et al. "Helicobacter Pylori and CagA Seropositivity and Its Association With Gastric and Oesophageal Carcinoma." Scandinavian Journal of Gastroenterology, vol. 42, no. 8, 2007, pp. 933-40.
Simán JH, Engstrand L, Berglund G, et al. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol. 2007;42(8):933-40.
Simán, J. H., Engstrand, L., Berglund, G., Forsgren, A., & Florén, C. H. (2007). Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scandinavian Journal of Gastroenterology, 42(8), pp. 933-40.
Simán JH, et al. Helicobacter Pylori and CagA Seropositivity and Its Association With Gastric and Oesophageal Carcinoma. Scand J Gastroenterol. 2007;42(8):933-40. PubMed PMID: 17613922.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. AU - Simán,J Henrik, AU - Engstrand,Lars, AU - Berglund,Göran, AU - Forsgren,Arne, AU - Florén,Claes-Henrik, PY - 2007/7/7/pubmed PY - 2007/10/30/medline PY - 2007/7/7/entrez SP - 933 EP - 40 JF - Scandinavian journal of gastroenterology JO - Scand. J. Gastroenterol. VL - 42 IS - 8 N2 - OBJECTIVE: Helicobacter pylori infection is an established risk factor for non-cardia gastric adenocarcinoma. Infection with H. pylori strains harbouring the cagA pathology island may augment this association. H. pylori infection may at the same time reduce the risk for oesophageal carcinoma. However, prospective data on the association between CagA seropositivity and gastric or oesophageal carcinomas are limited. The purpose of this study was to investigate whether CagA seropositivity among H. pylori seropositive subjects is associated with gastric or oesophageal carcinomas. MATERIAL AND METHODS: A nested case-control study was performed in the Malmö Preventive Medicine cohort consisting of 32,906 middle-aged subjects. Tumour cases were identified by the Swedish National Cancer Registry. The Western blot method Helicoblot 2.1 was used to detect H. pylori and CagA seropositivity. RESULTS: Non-cardia gastric adenocarcinoma was associated with H. pylori seropositivity, odds ratio 17.8 (95% CI: 4.2-74.8; 67 cases). The odds ratio for CagA seropositivity among H. pylori seropositive subjects was 9.7 (95% CI: 1.5-infinity). No significant associations were found between cardia gastric adenocarcinoma and H. pylori or CagA seropositivity among H. pylori seropositive subjects; odds ratios were 1.5 (95% CI: 0.51-4.8) and 2.7 (95% CI: 0.38-infinity), respectively (24 cases). Oesophageal adenocarcinoma and oesophageal squamous cell carcinoma were not significantly associated with H. pylori seropositivity or with CagA seropositivity among H. pylori seropositive subjects; the odds ratios associated with oesophageal adenocarcinoma were 0.46 (95% CI: 0.07-2.6) and 0.38 (95% CI: 0.02-24), respectively. Corresponding odds ratios for oesophageal squamous cell carcinoma were 0.44 (95% CI: 0.15-1.2; 37 cases) and 2.0 (95% CI: 0.24-infinity), respectively. CONCLUSIONS: CagA seropositivity among H. pylori seropositive subjects is a risk factor for non-cardia gastric adenocarcinoma. SN - 0036-5521 UR - https://www.unboundmedicine.com/medline/citation/17613922/Helicobacter_pylori_and_CagA_seropositivity_and_its_association_with_gastric_and_oesophageal_carcinoma_ L2 - http://www.tandfonline.com/doi/full/10.1080/00365520601173863 DB - PRIME DP - Unbound Medicine ER -